CAS: 154235-83-3; Piperidin-1-Yl(Quinoxalin-6-yl)Methanone

该化合物是一种化学化合物,其独特结构包括一个管状环和一种五氯硝酸盐.管状环是一个六人组成的饱和含氮的乙基环,而五氧线部分则有助于化合物的芳性和潜在的生物活动.该化合物通常具有诸如有机溶剂中的中溶性等特性,而且水中的溶性可能有限,许多环状化合物都存在这种特性.与五氧碱相联系的碳基化合物的存在,增强了其再活动性,并可能影响其在生物系统中的相互作用.由于已知的氟丙烯和五氧基结构具有各种生物影响,因此经常研究这种化合物的潜在药理特性,包括抗微生物或抗癌活动.

结构式图片

欧盟法规

C&L通报

上下游产品

6-喹喔啉羧酸 Quinoxaline-6-Carboxylic Acid 6925-00-4

合成工艺路线路线简述

    📜6-喹喔啉羧酸 反应生成安帕来斯
    参考文献: Drugs That Enhance Synaptic Responses Mediated By Ampa Receptors[fr] Medicaments Ameliorant Les Reponses Synaptiques Induites Par Les Recepteurs Ampa
    标题: Drugs That Enhance Synaptic Responses Mediated By Ampa Receptors[fr] Medicaments Ameliorant Les Reponses Synaptiques Induites Par Les Recepteurs Ampa
    摘要:(En) 披露了用于增强由ampa受体介导的突触反应的化合物,以及其制备方法和用于治疗因兴奋性突触数量或ampa受体数量不足而导致神经或智力功能受损的患者的方法.该发明化合物还可用于治疗非受损主体,以增强依赖于利用ampa受体的脑网络的感觉运动和认知任务的表现,并改善记忆编码. (Fr) 披露了用于增强由ampa受体介导的突触反应的化合物,以及其制备方法和用于治疗因兴奋性突触数量或ampa受体数量不足而导致神经或智力功能受损的患者的方法.该发明化合物还可用于治疗非受损主体,以增强依赖于利用ampa受体的脑网络的感觉运动和认知任务的表现,并改善记忆编码.

    海关参考信息

    专利信息


    专利号:WO-2024020091-A1
    优先权日:2022-07-19
    标 题 :Inhibitors of short-chain dehydrogenase activity for reducing glial fibrillary acidic protein levels
    发明人:MARKOWITZ SANFORD; PIEPER ANDREW
    权利人:UNIV CASE WESTERN RESERVE; THE US GOV AS REPRESENTED BY THE DEPARTMENT OF VETERAN AFFAIRS
    摘要:A method of decreasing blood glial fibrillary acidic protein (GFAP) levels in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor. Astroglia cells are the major and perhaps most abundant cell types in the brain. In healthy brain, astrocytes help with providing structural and network support for neurons and interface with the brain vasculature, including the blood-brain-barrier. Functionally, astrocytes are involved with providing neurotrophic factors (such as glial derived neurotrophic factor (GDNF)), and cytokine/chemokine release that influences the global and local inflammatory response environments, as well as working closely with neurons involved in the glutamate-glutamine synthesis/recycling pathway.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Gibert-Rahola J, Villena-Rodriguez A. Glutamatergic drugs for schizophrenia treatment. Actas Esp Psiquiatr. 2014 Sep;42(5):234-41. Epub 2014 Sep 1. Review. Epub 2006 Jun 19.
    5: Danysz W. CX-516 (Cortex Pharmaceuticals Inc). IDrugs. 1999 Aug;2(8):814-22. Review. Review. Review.

    合成参考文献


    参考文献:10.1016/j.pbb.2006.05.006
    摘要:Olsen CK, Kreilgaard M, Didriksen M. Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats. Pharmacol Biochem Behav. 2006 Jun;84(2):259–65. doi: 10.1016/j.pbb.2006.05.006.
    参考文献:10.1037/0735-7044.122.3.535
    摘要:Burke SN, Maurer AP, Yang Z, Navratilova Z, Barnes CA. Glutamate receptor-mediated restoration of experience-dependent place field expansion plasticity in aged rats. Behavioral Neuroscience. 2008;122(3):535–48. doi: 10.1037/0735-7044.122.3.535.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知